241 related articles for article (PubMed ID: 34160896)
1. A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics.
Wang L; Yan Y
Macromol Biosci; 2021 Sep; 21(9):e2100183. PubMed ID: 34160896
[TBL] [Abstract][Full Text] [Related]
2. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
3. One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA.
Khaled SZ; Cevenini A; Yazdi IK; Parodi A; Evangelopoulos M; Corbo C; Scaria S; Hu Y; Haddix SG; Corradetti B; Salvatore F; Tasciotti E
Biomaterials; 2016 May; 87():57-68. PubMed ID: 26901429
[TBL] [Abstract][Full Text] [Related]
4. Flash Nanoprecipitation Fabrication of PEI@Amorphous Calcium Carbonate Hybrid Nanoparticles for siRNA Delivery.
Ren Q; Wang L; Qian W; Chen B; Shuai Q; Yan Y
Macromol Biosci; 2023 Jul; 23(7):e2300085. PubMed ID: 37087721
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
[TBL] [Abstract][Full Text] [Related]
6. A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.
Jang M; Han HD; Ahn HJ
Sci Rep; 2016 Aug; 6():32363. PubMed ID: 27562435
[TBL] [Abstract][Full Text] [Related]
7. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
Kim B; Park JH; Sailor MJ
Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
[TBL] [Abstract][Full Text] [Related]
8. pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery.
Zhu H; Zhang S; Ling Y; Meng G; Yang Y; Zhang W
J Control Release; 2015 Dec; 220(Pt A):529-544. PubMed ID: 26590349
[TBL] [Abstract][Full Text] [Related]
9. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
11. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
12. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
15. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
16. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
17. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
Lu ZR; Laney VEA; Hall R; Ayat N
Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
[TBL] [Abstract][Full Text] [Related]
18. Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics.
Shen J; Zhang W; Qi R; Mao ZW; Shen H
Chem Soc Rev; 2018 Mar; 47(6):1969-1995. PubMed ID: 29417968
[TBL] [Abstract][Full Text] [Related]
19. Preparation, Characterization, and In Vitro Evaluation of Lipidoid-Polymer Hybrid Nanoparticles for siRNA Delivery to the Cytosol.
Thanki K; Zeng X; Foged C
Methods Mol Biol; 2019; 1943():141-152. PubMed ID: 30838614
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
